Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survivalin Patients with StageIIIc Ovarian Cancer

Objective:To evaluate the clinical efficacy and perioperative safety of cytoreductive surgery(CRS)in conjunction with hyperthermic intraperitonealchemotherapy(HIPEC)for treating patients with stage Ⅲc ovarian cancer.Methods:A total of 50 stage Ⅲc ovarian cancer patients were divided into the CRS(n=30),and the CRS + HIPEC group(n=24).The primary end point was overall survival(OS)and the second end points were serious adverse events(SAE).Results:The median follow-up was 44.1 months(6to 168 months)in CRS Group and 42.6months(10.5to 110.9 months)in CRS + HIPEC Group.The median OS was 27.1 months(95%CI,21.8-35.3 months)in CRS Group and 32.6 months(95%CI,24.8-40.6 months)in CRS + HIPEC Group(P0.05).Within 30 days after the surgery,SAE occurred in 3of the 30 patients in CRS Group,and in 5of the 24 patients in CRS+HIPEC Group(P=0.466).Multivariate analysis revealed that CRS + HIPEC,operation satisfaction,and chemotherapy over sixcycles were the independent factors for OS improvement.Conclusion:The CRS+HIPEC method improves the OS of stageⅢ c ovarian cancer patients,suggesting an acceptable safety.